Loading...
•
Mar 31, 2021
Repare Therapeutics Q1 2021 Earnings Report
Repare Therapeutics reported financial results for Q1 2021 and provided a business update.
Key Takeaways
Repare Therapeutics reported a net loss of $21.4 million for the first quarter of 2021. The company highlighted the progress of its RP-3500 and RP-6306 programs and announced the enrollment of the first patient in the RP-6306 Phase 1 clinical trial.
Advanced the Phase 1/2 clinical development of ATR inhibitor RP-3500, with initial results expected from the monotherapy arm of the trial in the second half of 2021.
The PARP inhibitor and RP-3500 combination arm is now recruiting.
First patient has been dosed in Phase 1 clinical trial of RP-6306, materially ahead of the initial timeline.
Highlighted program progress and introduced PKMYT1 as synthetic-lethal target to CCNE1 and FBXW7 at RP-6306 Virtual Investor Day Event.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...